Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alicaforsen enema for active chronic antibiotic-refractory primary idiopathic pouchitis
NL-OMON46082Phase 3Active, not recruiting
- Sponsor
- Atlantic Pharmaceuticals
- Start
- Jun 2016
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pouchitis comparing Alicaforsen enema with Placebo enema (2 arms). Primary endpoints: Endoscopic remission at Week 10 and Stool frequency improvement at Week 10. Started Jun 2016; status: active, not recruiting.
02
Drugs
alicaforsen
03
Conditions
pouchitis
Beyond the preview
Go deeper on NL-OMON46082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46082.